The Use of normal human immunoglobulin (NHIG) for public health purposes in Queensland 2004-2014 and Australia 2014-2016
DOI:
https://doi.org/10.33321/cdi.2019.43.9Keywords:
communicable diseases, normal human immunoglobulin, passive immunisation, measles, rubella, hepatitis AAbstract
Objective
To describe the use of normal human immunoglobulin (NHIG) recommended for public health purposes in Queensland and Australia.
Methods
Queensland public health unit (PHU) data on notified cases of measles, rubella and hepatitis A from 2004 to 2014 were examined; particularly regarding the number of contacts offered NHIG and the volume recommended per contact.
The National Blood Authority (NBA) provided unidentified data from NHIG order form inception (June 2014) through December 2016. Queensland orders were compared to PHU data where the data timeframes overlapped.
Results
NHIG usage varied by condition. For hepatitis A, usage declined after the introduction of vaccination for contacts in 2010. Usage fluctuated across the study period for measles and was not recommended for rubella. Average volumes per contact for hepatitis A and measles were 1.6mL and 11.9mL respectively based on PHU data.
PHU data approximated NBA data on NHIG usage for hepatitis A and rubella contacts. Calculated volumes of NHIG per measles contact were also similar, but PHU data underestimated the number of measles contacts for whom NHIG was ordered.
Discussion
This study is the first to document the use of NHIG for public health purposes in Australia. Results will be valuable for national blood sufficiency planning and cost effectiveness studies in the event of alterations to NHIG dosage recommendations.
Downloads
References
CSL Behring. Plasma Fractionation for Australia 2017 [cited 2017 December 8]. Available from: http://www.cslbehring.com.au/s1/cs/auau/1255930481887/page/1199978997135/BusinessUnit.htm.
Farrugia A, Cassar J. Plasma-derived medicines: access and usage issues. Blood Transfus. 2012;10:273-8.
National Blood Authority Australia. National Immunoglobulin Governance Program [cited 2017 December 8]. Available from: https://www.blood.gov.au/Ig-program.
Communicable Diseases Network Australia. Measles: National guidelines for public health units. Canberra: Commonwealth Department of Health; 2015.
Communicable Diseases Network Australia. Hepatitis A: National guidelines for public health units. Canberra: Commonwealth Department of Health; 2009.
Queensland Health. Rubella: Queensland Health Guidelines for public health units. Brisbane: Queensland Government; 2015.
Young M, Cripps A, Nimmo G, van Driel M. Post-exposure passive immunisation for preventing rubella and congenital rubella syndrome. Cochrane Database of Systematic Reviews. 2015;Issue 9. Art. No.: CD010586. DOI: 10.1002/14651858.CD010586.pub2.
Young M, Nimmo G, Cripps A, Jones M. Post-exposure passive immunisation for preventing measles. Cochrane Database of Systematic Reviews. 2014; Issue 4. Art. No: CD010056. DOI: 10.1002/14651858.CD010056.pub2.
Liu J, Nikolova D, Fei Y. Immunoglobulins for preventing hepatitis A. Cochrane Database of Systematic Reviews. 2009; Issue 2, Art. No.: CD004181. DOI: 10.1002/14651858.CD004181.pub2.
Ramsay M, Manikkavasagan G, Brown K, Craig L. Post exposure prophylaxis for measles: revised guidance May 2009. UK: Health Protection Agency; 2009.
Starship Children’s Health Clinical Guideline, Best, Voss, Roberts, Freeman. Measles - Infection Control Definitions & Guidelines Auckland, New Zealand: Auckland District Health Board; October 2011 [Available from: http://www.adhb.govt.nz/starshipclinicalguidelines/_Documents/Measles.pdf.]
Sinden J. Post exposure prophylaxis for measles New Zealand: NZBlood; 2012 Jan 4 [Available from: http://www.nzblood.co.nz/assets/Transfusion-Medicine/PDFs/POST-EXPOSURE-PROPHYLAXIS-FOR-MEASLES-111G001.pdf.
Young M, Bertolini J, Kotharu P, Maher D, Cripps A. Do Australian immunoglobulin products meet international measles antibody titre standards? Human Vaccines and Immunotherapeutics. 2016; 13 (3): 607-612. DOI: 10.1080/21645515.2016.1234554
Young M, Bertolini J, Kotharu P, Maher D, Cripps A. Rubella antibodies in Australian immunoglobulin products. Human Vaccines and Immunotherapeutics. 2017;Issue 8, published online 12 June, DOI: 10.1080/21645515.2017.1327110.
Victorian State Government. Growth charts Victoria, Australia: State Government of Victoria; 2017 July 7 [cited 9 September 2017]. Available from: http://www.education.vic.gov.au/childhood/parents/mch/Pages/charts.aspx.
Australian Bureau of Statistics. 4841.0 Facts at your Fingertips: Health, 2011 - Measuring Australians Canberra, Australia: Commonwealth of Australia; 2012 July 24 [cited 2017 Sept 15]. Available from: http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/4841.02011?OpenDocument
Australian Government Department of Health. National Notifiable Diseases Surveillance System: number of notifications of measles received from State and Territory health authorities in the period of 1991 to 2016 and year-to-date notifications for 2017 2017 [cited 2017 December 15]. Available from: http://www9.health.gov.au/cda/source/rpt_4.cfm.
Published
How to Cite
License
Copyright (c) 2019 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
